TY 2021 Form 990

(A) Name and title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)	(E) Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)
(1) Diana Clynes...................................................................... Executive Director	37.50 .................	X	X	150,000	0	0
(2) Richard Knight...................................................................... President	1.00 .................	X	X	0	0	0
(3) Edward V Hickey...................................................................... Vice President	1.00 .................	X	X	0	0	0
(4) Suzanne Ruff...................................................................... Treasurer	1.00 .................	X	X	0	0	0
(5) Dale Rogers...................................................................... Secretary	1.00 .................	X	X	0	0	0
(6) Kent Bressler...................................................................... Board Member	1.00 .................	X		0	0	0
(7) Jennifer L Jones...................................................................... Board Member	1.00 .................	X		0	0	0
(8) Paul T Conway...................................................................... Past President	1.00 .................	X		0	0	0
(9) Sara E Schaeffer...................................................................... Board Member	1.00 .................	X		0	0	0
(10) Barry H Smith MD PhD...................................................................... Board Member	1.00 .................	X		0	0	0
(11) Janice Lea MD MSC FASN...................................................................... Board Member	1.00 .................	X		0	0	0
(12) James W Myers III...................................................................... Board Member	1.00 .................	X		0	0	0
(13) David Rodriquez...................................................................... Board Member	1.00 .................	X		0	0	0
(14) Lana Schmidt MBA...................................................................... Board Member	1.00 .................	X		0	0	0
(15) Catherine Campbell DNP RN MBA...................................................................... Board Member	1.00 .................	X		0	0	0

(A)
Name and title

(B)
Average hours per week (list any hours for related organizations below dotted line)

(D)
Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)

(E)
Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)

(F)
Estimated amount of other compensation from the organization and related organizations

(1) Diana Clynes......................................................................
Executive Director

37.50
.................

150,000

(2) Richard Knight......................................................................
President

1.00
.................

(3) Edward V Hickey......................................................................
Vice President

1.00
.................

(4) Suzanne Ruff......................................................................
Treasurer

1.00
.................

(5) Dale Rogers......................................................................
Secretary

1.00
.................

(6) Kent Bressler......................................................................
Board Member

1.00
.................

(7) Jennifer L Jones......................................................................
Board Member

1.00
.................

(8) Paul T Conway......................................................................
Past President

1.00
.................

(9) Sara E Schaeffer......................................................................
Board Member

1.00
.................

(10) Barry H Smith MD PhD......................................................................
Board Member

1.00
.................

(11) Janice Lea MD MSC FASN......................................................................
Board Member

1.00
.................

(12) James W Myers III......................................................................
Board Member

1.00
.................

(13) David Rodriquez......................................................................
Board Member

1.00
.................

(14) Lana Schmidt MBA......................................................................
Board Member

1.00
.................

(15) Catherine Campbell DNP RN MBA......................................................................
Board Member

1.00
.................

(A)
Name and title

(B)
Average hours per week (list any hours for related organizations below dotted line)

(D)
Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)

(E)
Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)

(F)
Estimated amount of other compensation from the organization and related organizations

(A)
Name and business address

(B)
Description of services

Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization MediumBullet

- TIN:

SCHEDULE A
(Form 990)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.
right arrow

Attach to Form 990 or Form 990-EZ.
right arrow

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021

Open to Public
Inspection

Name of the organization

American Association of Kidney Patients
Inc

Employer identification number

11-2306416

Part I

Reason for Public Charity Status (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)

A church, convention of churches, or association of churches described in section 170(b)(1)(A)(i).

A school described in section 170(b)(1)(A)(ii). (Attach Schedule E (Form 990).)

A hospital or a cooperative hospital service organization described in section 170(b)(1)(A)(iii).

A medical research organization operated in conjunction with a hospital described in section 170(b)(1)(A)(iii). Enter the hospital's name, city, and state:

An organization operated for the benefit of a college or university owned or operated by a governmental unit described in section 170(b)(1)(A)(iv). (Complete Part II.)

A federal, state, or local government or governmental unit described in section 170(b)(1)(A)(v).

An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in section 170(b)(1)(A)(vi). (Complete Part II.)

A community trust described in section 170(b)(1)(A)(vi). (Complete Part II.)

An agricultural research organization described in 170(b)(1)(A)(ix) operated in conjunction with a land-grant college or university or a non-land grant college of agriculture. See instructions. Enter the name, city, and state of the college or university:

An organization that normally receives: (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See section 509(a)(2). (Complete Part III.)

An organization organized and operated exclusively to test for public safety. See section 509(a)(4).

An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2). See section 509(a)(3). Check the box on lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g.

Type I. A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization. You must complete Part IV, Sections A and B.

Type II. A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s). You must complete Part IV, Sections A and C.

Type III functionally integrated. A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions). You must complete Part IV, Sections A, D, and E.

Type III non-functionally integrated. A supporting organization operated in connection with its supported organization(s) that is not functionally integrated. The organization generally must satisfy a distribution requirement and an attentiveness requirement (see instructions). You must complete Part IV, Sections A and D, and Part V.

Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization.

Enter the number of supported organizations ...............................

Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iv) Is the organization listed in your governing document?		(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
(i) Name of supported organization	(ii) EIN	Yes	No	(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)


Total

For Paperwork Reduction Act Notice, see the Instructions for
Form 990 or 990-EZ.

Cat. No. 11285F

Schedule A (Form 990) 2021

Page 2

Part II

Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization failed to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2017	(b) 2018	(c) 2019	(d) 2020	(e) 2021	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") ..	573,211	1,151,107	990,174	1,196,542	1,944,903	5,855,937
2	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....
3	The value of services or facilities furnished by a governmental unit to the organization without charge..
4	Total. Add lines 1 through 3	573,211	1,151,107	990,174	1,196,542	1,944,903	5,855,937
5	The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) ..
6	Public support. Subtract line 5 from line 4.						5,855,937

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2017	(b) 2018	(c) 2019	(d) 2020	(e) 2021	(f) Total
7	Amounts from line 4..	573,211	1,151,107	990,174	1,196,542	1,944,903	5,855,937
8	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources...
9	Net income from unrelated business activities, whether or not the business is regularly carried on..	58,432	82,732	39,648	26,852	49,535	257,199
10	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)..	3,677	1,471	355	1,412	1,033	7,948
11	Total support. Add lines 7 through 10						6,121,084

Gross receipts from related activities, etc. (see instructions) ..................

First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here ........................................ right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2021 (line 6, column (f) divided by line 11, column (f)) .........

95.670 %

Public support percentage for 2020 Schedule A, Part II, line 14 ...............

94.010 %

16a

33 1/3% support test—2021. If the organization did not check the box on line 13, and line 14 is 33 1/3 % or more, check this box
and stop here. The organization qualifies as a publicly supported organization ....................... right arrow

33 1/3% support test—2020. If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this
box and stop here. The organization qualifies as a publicly supported organization ..................... right arrow

17a

10%-facts-and-circumstances test—2021. If the organization did not check a box on line 13, 16a, or 16b, and line 14
is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain
in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported
organization ..................................................... right arrow

10%-facts-and-circumstances test—2020. If the organization did not check a box on line 13, 16a, 16b, or 17a, and line
15 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here.
Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly
supported organization ................................................ right arrow

Private foundation. If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see
instructions ..................................................... right arrow

Schedule A (Form 990) 2021

Page 3

Part III

Support Schedule for Organizations Described in Section 509(a)(2)
(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2017	(b) 2018	(c) 2019	(d) 2020	(e) 2021	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .
2	Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose
3	Gross receipts from activities that are not an unrelated trade or business under section 513 .....
4	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf...
5	The value of services or facilities furnished by a governmental unit to the organization without charge
6	Total. Add lines 1 through 5
7a	Amounts included on lines 1, 2, and 3 received from disqualified persons
b	Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year.
c	Add lines 7a and 7b..
8	Public support. (Subtract line 7c from line 6.)

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2017	(b) 2018	(c) 2019	(d) 2020	(e) 2021	(f) Total
9	Amounts from line 6...
10a	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..
b	Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975.
c	Add lines 10a and 10b.
11	Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on.
12	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) ..
13	Total support. (Add lines 9, 10c, 11, and 12.)..

First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization,
check this box and stop here............................................. right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2021 (line 8, column (f) divided by line 13, column (f)) .........

Public support percentage from 2020 Schedule A, Part III, line 15 ...............

Section D. Computation of Investment Income Percentage

Investment income percentage for 2021 (line 10c, column (f) divided by line 13, column (f)) ......

Investment income percentage from 2020 Schedule A, Part III, line 17 .............

19a

331/3% support tests—2021. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ....... right arrow

33 1/3% support tests—2020. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization .... right arrow

Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions .... right arrow

Schedule A (Form 990) 2021

Page 4

Part IV

Supporting Organizations

(Complete only if you checked a box on line 12 of Part I. If you checked box 12a, of Part I, complete Sections A and B. If you checked box 12b, of Part I, complete Sections A and C. If you checked box 12c, of Part I, complete Sections A, D, and E. If you checked box12d, of Part I, complete Sections A and D, and complete Part V.)

Section A. All Supporting Organizations

Yes

Are all of the organization’s supported organizations listed by name in the organization’s governing documents?
If "No," describe in Part VI how the supported organizations are designated. If designated by class or purpose,
describe the designation. If historic and continuing relationship, explain.

Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? If "Yes," explain in Part VI how the organization determined that the supported organization was described in section 509(a)(1) or (2).

Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? If "Yes," answer lines 3b and 3c below.

Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? If "Yes," describe in Part VI when and how the organization made the determination.

Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? If "Yes," explain in Part VI what controls the organization put in place to ensure such use.

Was any supported organization not organized in the United States ("foreign supported organization")? If “Yes” and if you checked box 12a or 12b in Part I, answer lines 4b and 4c below.

Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? If “Yes,” describe in Part VI how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.

Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? If “Yes,” explain in Part VI what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.

Did the organization add, substitute, or remove any supported organizations during the tax year? If “Yes,” answer lines 5b and 5c below (if applicable). Also, provide detail in Part VI, including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).

Type I or Type II only. Was any added or substituted supported organization part of a class already designated in the organization's organizing document?

Substitutions only. Was the substitution the result of an event beyond the organization's control?

Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization’s supported organizations? If “Yes,” provide detail in Part VI.

Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? If “Yes,” complete Part I of Schedule L (Form 990) .

Did the organization make a loan to a disqualified person (as defined in section 4958) not described on line 7? If “Yes,” complete Part I of Schedule L (Form 990).

Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons, as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? If “Yes,” provide detail in Part VI.

Did one or more disqualified persons (as defined on line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? If “Yes,” provide detail in Part VI.

Did a disqualified person (as defined on line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? If “Yes,” provide detail in Part VI.

10a

Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? If “Yes,” answer line 10b below.

10a

Did the organization have any excess business holdings in the tax year? (Use Schedule C, Form 4720, to determine whether the organization had excess business holdings).

10b

Schedule A (Form 990) 2021

Page 5

Part IV

Supporting Organizations (continued)

Yes

Has the organization accepted a gift or contribution from any of the following persons?

A person who directly or indirectly controls, either alone or together with persons described on lines 11b and 11c below, the governing body of a supported organization?

11a

A family member of a person described on 11a above?

11b

A 35% controlled entity of a person described on line 11a or 11b above? If “Yes” to 11a, 11b, or 11c, provide detail in Part VI.

11c

Section B. Type I Supporting Organizations

Yes

Did the officers, directors, trustees, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization’s directors or trustees at all times during the tax year? If “No,” describe in Part VI how the supported organization(s) effectively operated, supervised, or controlled the organization’s activities. If the organization had more than one supported organization, describe how the powers to appoint and/or remove directors or trustees were allocated among the supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.

Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization? If “Yes,” explain in Part VI how providing such benefit carried out the purposes of the supported organization(s) that operated, supervised or controlled the supporting organization.

Section C. Type II Supporting Organizations

Yes

Were a majority of the organization’s directors or trustees during the tax year also a majority of the directors or trustees of each of the organization’s supported organization(s)? If “No,” describe in Part VI how control or management of the supporting organization was vested in the same persons that controlled or managed the supported organization(s).

Section D. All Type III Supporting Organizations

Yes

Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization’s tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization’s governing documents in effect on the date of notification, to the extent not previously provided?

Were any of the organization’s officers, directors, or trustees either (i) appointed or elected by the supported organization(s) or (ii) serving on the governing body of a supported organization? If "No," explain in Part VI how the organization maintained a close and continuous working relationship with the supported organization(s).

By reason of the relationship described in line 2 above, did the organization’s supported organizations have a significant voice in the organization’s investment policies and in directing the use of the organization’s income or assets at all times during the tax year? If "Yes," describe in Part VI the role the organization’s supported organizations played in this regard.

Section E. Type III Functionally-Integrated Supporting Organizations

Check the box next to the method that the organization used to satisfy the Integral Part Test during the year (see instructions):

The organization satisfied the Activities Test. Complete line 2 below.

The organization is the parent of each of its supported organizations. Complete line 3 below.

The organization supported a governmental entity. Describe in Part VI how you supported a government entity (see instructions)

Activities Test. Answer lines 2a and 2b below.

Yes

Did substantially all of the organization’s activities during the tax year directly further the exempt purposes of the supported organization(s) to which the organization was responsive? If "Yes," then in Part VI identify those supported organizations and explain how these activities directly furthered their exempt purposes, how the organization was responsive to those supported organizations, and how the organization determined that these activities constituted substantially all of its activities.

Did the activities described on line 2a, above constitute activities that, but for the organization’s involvement, one or more of the organization’s supported organization(s) would have been engaged in? If "Yes," explain in Part VI the reasons for the organization’s position that its supported organization(s) would have engaged in these activities but for the organization’s involvement.

Parent of Supported Organizations. Answer lines 3a and 3b below.

Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees of each of the supported organizations?If "Yes" or "No", provide details in Part VI.

Did the organization exercise a substantial degree of direction over the policies, programs and activities of each of its supported organizations? If "Yes," describe in Part VI. the role played by the organization in this regard.

Schedule A (Form 990) 2021

Page 6

Part V

Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations

Check here if the organization satisfied the Integral Part Test as a qualifying trust on Nov. 20, 1970 (explain in Part VI). See instructions. All other Type III non-functionally integrated supporting organizations must complete Sections A through E.

	Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1	Net short-term capital gain	1
2	Recoveries of prior-year distributions	2
3	Other gross income (see instructions)	3
4	Add lines 1 through 3	4
5	Depreciation and depletion	5
6	Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions)	6
7	Other expenses (see instructions)	7
8	Adjusted Net Income (subtract lines 5, 6 and 7 from line 4)	8

	Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1	Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year):	1
a	Average monthly value of securities	1a
b	Average monthly cash balances	1b
c	Fair market value of other non-exempt-use assets	1c
d	Total (add lines 1a, 1b, and 1c)	1d
e	Discount claimed for blockage or other factors (explain in detail in Part VI):
2	Acquisition indebtedness applicable to non-exempt use assets	2
3	Subtract line 2 from line 1d	3
4	Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions).	4
5	Net value of non-exempt-use assets (subtract line 4 from line 3)	5
6	Multiply line 5 by 0.035	6
7	Recoveries of prior-year distributions	7
8	Minimum Asset Amount (add line 7 to line 6)	8

	Section C - Distributable Amount		Current Year
1	Adjusted net income for prior year (from Section A, line 8, Column A)	1
2	Enter 85% of line 1	2
3	Minimum asset amount for prior year (from Section B, line 8, Column A)	3
4	Enter greater of line 2 or line 3	4
5	Income tax imposed in prior year	5
6	Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions)	6

Check here if the current year is the organization's first as a non-functionally-integrated Type III supporting organization (see instructions)

Schedule A (Form 990) 2021

Page 7

Part V

Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations(continued)

Section D - Distributions		Current Year
1 Amounts paid to supported organizations to accomplish exempt purposes	1
2 Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity	2
3 Administrative expenses paid to accomplish exempt purposes of supported organizations	3
4 Amounts paid to acquire exempt-use assets	4
5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI)	5
6 Other distributions (describe in Part VI). See instructions	6
7Total annual distributions. Add lines 1 through 6.	7
8 Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions	8
9 Distributable amount for 2021 from Section C, line 6	9
10 Line 8 amount divided by Line 9 amount	10

Section E - Distribution Allocations (see instructions)		(i) Excess Distributions	(ii) Underdistributions Pre-2021	(iii) Distributable Amount for 2021
1 Distributable amount for 2021 from Section C, line 6
2 Underdistributions, if any, for years prior to 2021 (reasonable cause required-- explain in Part VI). See instructions.
3 Excess distributions carryover, if any, to 2021:
a From 2016.......
b From 2017.......
c From 2018.......
d From 2019.......
e From 2020.......
fTotal of lines 3a through e
g Applied to underdistributions of prior years
h Applied to 2021 distributable amount
i Carryover from 2016 not applied (see instructions)
j Remainder. Subtract lines 3g, 3h, and 3i from line 3f.
4Distributions for 2021 from Section D, line 7:
$
a Applied to underdistributions of prior years
b Applied to 2021 distributable amount
c Remainder. Subtract lines 4a and 4b from line 4.
5 Remaining underdistributions for years prior to 2021, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions.
6 Remaining underdistributions for 2021. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions.
7 Excess distributions carryover to 2022. Add lines 3j and 4c.
8 Breakdown of line 7:
a Excess from 2017.....
b Excess from 2018.....
c Excess from 2019.....
d Excess from 2020.....
e Excess from 2021.....

Schedule A (Form 990) (2021)

Schedule A (Form 990) 2021

Page 8

Part VI

Supplemental Information. Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a and 3b; Part V, line 1; Part V, Section B, line 1e; Part V Section D, lines 5, 6, and 8; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information. (See instructions).

Facts And Circumstances Test

Return Reference	Explanation

Schedule A (Form 990) 2021

Additional Data

Software ID:
Software Version:

	(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year .........
2	Aggregate value of contributions to (during year)
3	Aggregate value of grants from (during year)
4	Aggregate value at end of year ........


a	Total number of conservation easements ......................	2a
b	Total acreage restricted by conservation easements ....................	2b
c	Number of conservation easements on a certified historic structure included in (a) .....	2c
d	Number of conservation easements included in (c) acquired after 7/25/06, and not on a historic structure listed in the National Register ...	2d


b	If "Yes," explain the arrangement in Part XIII and complete the following table:		Amount
c	Beginning balance .............................	1c
d	Additions during the year ............................	1d
e	Distributions during the year ..........................	1e
f	Ending balance ................................	1f

(a) Name and address of organization
or government

(b) EIN

(c) IRC section
(if applicable)

(d) Amount of cash grant

(e) Amount of non-cash
assistance

(f) Method of valuation
(book, FMV, appraisal,
other)

(g) Description of
noncash assistance

(h) Purpose of grant
or assistance

(1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

(9)

(10)

(11)

(12)

- TIN:

SCHEDULE O
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or 990-EZ or to provide any additional information.
MediumBullet

Attach to Form 990 or 990-EZ.
MediumBullet

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2021

Open to Public
Inspection

Name of the organization

American Association of Kidney Patients
Inc

Employer identification number

11-2306416

Return Reference	Explanation
Program Service Accomplishments Line 4d: National Awards Program	AAKP's awards encompass two major categories. The first category includes Legacy Awards - awards that AAKP has extended to organizations and professionals for several decades. The second category encompasses Patient Engagement and Advocacy Awards - awards created over the course of the past several years through AAKP's new Center for Patient Engagement and Advocacy as a means of recognizing the increased influence patients have on national policymakers and healthcare deliberations. Legacy Awards: President's Award Presented to an individual who made a long-term commitment toward advancement and evolvement of AAKP's national strategy. Samuel J. Orenstein Award Presented to an individual who consistently renders extraordinary service toward the achievement of AAKP's goals, objectives and national strategy. Peter Lundin, MD Award Presented to a renal physician who has made contributions to the care, welfare and well-being of patients over a lifetime of devoted service. Dominick Gentile, MD Memorial Award Presented to an ESRD Network that has developed and maintained a program which has significantly benefited patients and demonstrated sustainability. Kidney Patient Support Group of the Year Presented to a kidney patient support group that has been active within their local community. This support group should have hosted community educational programs and activities to support its local patients and raise awareness of kidney disease. Patient Engagement and Advocacy Awards: National Social Media Education and Advocacy Award Presented to an individual and organization each who has demonstrated a national level of excellence through social media to either educate or advocate on behalf of kidney patients and their loved ones in the areas of disease awareness, policy advocacy or the creation of online communities. This highly competitive award will recognize excellence on a variety of social media platforms and will include video, bloggers and social media content and sites that have grown large audiences through creative and effective use of social media. National Patient Engagement and Advocacy Award Presented to an individual, organization and public servant each who are recognized leaders in the field of kidney patient education and advocacy and whose body of professional work and commitment to advance the interests of kidney patients through policy, education or activism. National Journalism Award Presented to a reporter or journalist whose work in either print, online, television or web arena(s) has brought the needs and interests of the kidney patient community to the national forefront through journalistic excellence. Presented either for a single compelling story with local, regional or national significance, or body of work, which over time has informed Americans of the critical needs and concerns of the kidney patient community. National Public Service Award Presented to a public servant whose body of professional work and commitment to advance the interests and well-being of the Nation's kidney patient population through policy, education and activism. Past awardees include Dr. Carolyn Neuland, the U.S. Food and Drug Administration; Dr. Priti Patel, Centers for Disease Control and Prevention; Dr. Robert Star, National Institute of Health; and Elena Balovlenkov, MS, RN, CHH, Centers for Medicare and Medicaid Services; and Dr. Paul Kimmel, National Institute of Health. Medal of Excellence The AAKP Medal of Excellence honors health care professionals who have made significant contributions to the advancement and evolution of direct patient care; encouraged the expansion of the patient engagement model within the renal community; and enhanced the quality of life for kidney patients and their families. The 2021 Medal of Excellence recipients are recognized throughout the calendar year. The 2022 Medal of Excellence Award recipients: Special Recognition - Breakthrough Innovations Category: Shuvo Roy, PhD (San Francisco, CA), 2021 KidneyX Artificial Kidney Prize Winner; Technical Director, The Kidney Project; and Professor, Departments of Bioengineering and Therapeutic Sciences and Surgery, is recognized for his excellence regarding innovations in support of artificial implantable organs through the leadership of The Kidney Project. Robert Montgomery, MD, DPhil, FACS (New York, NY), Chair of the Department of Surgery, Director of the NYU Langone Transplant Institute, and heart transplant recipient, is recognized for his excellence regarding xenotransplantation. Nephrologist/Physician Category: William H. Fissell, IV, MD (Nashville, TN), Medical Director, The Kidney Project, and Associate Professor of Clinical Medicine, Vanderbilt University Medical Center. Transplant Surgeon Category: Juan Carlos Caicedo, MD, FACS (Chicago, IL), Professor of Surgery and a multi-organ adult and pediatric Transplant Surgeon at Northwestern Memorial Hospital and Lurie Children's Hospital; Surgical Director of the Northwestern Liver Transplant Program; and Director of the Living Donor Liver Transplant Program and Hepatobiliary Surgery. Robert M. Merion, MD, FACS (Ann Arbor, MI), Professor Emeritus of Surgery, University of Michigan; Distinguished Research Scientist, Arbor Research Collaborative for Health; and former President/CEO, Arbor Research Collaborative for Health (2009-2021). Transplant Professional Category: Elisa J. Gordon, PhD, MPH (Chicago, IL), Professor, Department of Surgery-Division of Transplantation, Center for Health Services and Outcomes Research, and Center for Bioethics & Medical Humanities, Northwestern University Feinberg School of Medicine. Nursing Category: Miranda Kilby, DNP, FNP (Shelby, NC), Nurse Practitioner at Nephrology Associates of the Carolinas. Dietetic Category: Emily Greenough, RD, CSR, CD (Longview, WA), Renal Dietitian, Fresenius Kidney Care, Pacific Northwest. Dialysis Technician Category: William Macias, CHT (San Jose, CA), Biomedical Applications Manager, Satellite Healthcare. Social Worker Category: Helen Rose, MSW, LCSW (Tampa, FL), Executive Director, ESRD Networks 7, 13, 15, 17, and 18. Presidential Volunteer Service Awards AAKP is a PVSA-authorized and certifying organization and the largest organization in the kidney space that participates in this important American initiative. In 2020, AAKP launched its inaugural PVSA program, and twenty-nine kidney advocates received recognition from President Donald J. Trump for their work to educate high-risk immunosuppressed and immunocompromised kidney patients on threats posed by COVID-19. The PVSA was founded by President George W. Bush in the aftermath of the terror attacks of September 11, 2001, as one of several initiatives, including the President's Council on Service and Civic Participation, designed to encourage and exemplify the strength of outstanding American volunteerism and community engagement. The award program has continued under successive presidential administrations. The PVSA program is led by AmeriCorps (formerly the Corporation for National and Community Service), an organization whose vision originated in the administration of President William J. Clinton, and is managed in partnership with Points of Light, an organization whose vision is rooted in the administration of President George H.W. Bush. In 2022, President Joseph R. Biden recognized a number of AAKP patients and advocates with a U.S. PVSA. Six AAKP leaders received the President's Lifetime Achievement Award, the highest level of recognition that is unique and recognizes an exemplary level of volunteerism to build a stronger nation through volunteer service, including the investment of thousands of hours of personal time and professional expertise. The AAKP members who received the Presidential Lifetime Achievement Award, as well as PVSA awards at the gold, silver, and bronze levels, are nationally known advocates deeply involved in efforts to impact kidney science, innovation, and policy through collaborations with top kidney scientists, elected and appointed leaders, federal agencies, investors, major companies and startups, and nearly every major academic research center and university involved in kidney research.
Form 990, Part VI, Section B, line 11b	The Form 990 is reviewed in detail by the Executive Committee and Finance Committee. Both Committees approve the return. Copies of the Form 990 are provided to all Board members prior to the return being filed.
Form 990, Part VI, Section B, line 12c	All members of the Board of Directors and employees of AAKP receive a copy of the conflict of interest policy. The Executive Director and all Board members are required to complete and sign the Conflict of Interest Questionnaire and Confidentiality Agreement indicating that they have been and are in compliance with this policy.
Form 990, Part VI, Section B, line 15a	The President conducts an annual review of the Executive Director's performance and recommends any adjustment to salary to the Executive Committee. The Executive Committee approves raises for the Executive Director and approves the overall salary levels for all employees.
Form 990, Part VI, Section C, line 18	The Form 990 is reviewed in detail by the Executive Committee and Finance Committee. Both Committees approve the return. Copies of the Form 990 are provided to all Board members prior to the return being filed. The Final 990 and Audit is made available on the organization website.
Form 990, Part VI, Section C, line 19	The Final 990 and Audit is made available on the organization website.
Program Service Accomplishments Line 4d: National Awards Program	President's Lifetime Achievement Award: " Richard Knight (MD), former dialysis patient,16-year transplant recipient; AAKP President; Member, National Institutes of Health/NIDDK Strategic Planning Committee; Co-Chair, Community Engagement Committee, NIH/NIDDK Kidney Precision Medicine Project; Member, Scientific Registry of Transplant Recipients (SRTR) Visiting Committee; 2017 recipient, American Society of Nephrology's President's Medal; 2020 PVSA recipient " Edward V. Hickey III (CA), USMC veteran, kidney patient; AAKP Vice President; Chair of AAKP Veterans Health Initiative (VHI); Reviewer, Department of Defense Congressionally Directed Medical Research Program; AAKP liaison, U.S. Department of Veterans Affairs; Member, Judging Panel, U.S. Department of Health and Human Services/American Society of Nephrology KidneyX COVID-19 Kidney Care Challenge; 2020 PVSA recipient " Paul T. Conway (VA), former dialysis patient, 25-year transplant recipient; AAKP Chair of Public Policy and Global Affairs; Co-Chair, AAKP/George Washington University Global Summit on Kidney Disease Innovations; Member, American Board of Internal Medicine's Nephrology Specialty Board; Chair, FDA Patient Engagement Advisory Committee; Member, Observational Study Monitoring Board, National Institutes of Health/NIDDK Kidney Precision Medicine Project; 2017 recipient, American Society of Nephrology's President's Medal; 2020 PVSA recipient " Suzanne Ruff (NC), living organ donor; author, The Reluctant Donor; freelance writer, Charlotte Observer; AAKP National Board of Director and National Ambassador; 2020 PVSA recipient " Dr. Stephen Fadem (TX), patient, Clinical Professor of Medicine, Baylor College of Medicine, Section of Nephrology; Chair, AAKP Medical Advisory Board; AAKP Life Member; Recipient, AAKP's Samuel J. Orenstein and Peter Lundin, MD Awards; AAKP Historian; recipient of AAKP Lifetime Achievement Award; 2020 PVSA recipient " Bob Abbott (AR), caregiver; Charter Member, Arkansas Kidney Disease Commission; AAKP Life Member; recipient, AAKP Samuel J. Orenstein Award (2011); recipient, 2019 AAKP National Patient Engagement and Advocacy Award; 2020 PVSA recipient PVSA Gold Medal: " Kent Bressler, MA, RN (TX), U.S. Army veteran, pre-emptive transplant recipient; AAKP National Board of Director and National Ambassador; Reviewer, Department of Defense CDMRP; Co-founder of Kidney Solutions; and host of Kent's Kidney Stories Podcast series; 2020 PVSA recipient " Jennifer Jones (VA), USMC veteran, former dialysis patient, current transplant recipient; AAKP National Board of Director and National Ambassador; 2019 recipient of AAKP National Social Media Education and Advocacy Award; 2020 PVSA recipient " Dr. Janice Lea (GA), Professor of Medicine, Emory University; CMO, Emory Dialysis; AAKP National Board of Director; 2019 recipient, AAKP Samuel J. Orenstein Award; Principal Investigator, AAKP PCORI Engagement Awards; 2020 PVSA recipient " Dr. Dominic Raj (VA), Professor and Director, the Division of Kidney Diseases and Hypertension, George Washington University School of Medicine and Health Sciences; Co-chair, AAKP/GWU Global Summit on Kidney Innovations; 2019 recipient, AAKP Peter Lundin, MD Award; 2020 PVSA recipient " Glenda Roberts (WA), former dialysis patient; current transplant recipient; Director, External Relations and Patient Engagement, the Kidney Research Institute (KRI); AAKP National Ambassador; Member, Patient Advisory Board for Center for Dialysis Innovation; former Executive Director, Transplant House; 2020 PVSA recipient " David Rodriguez (TX), former dialysis patient, current transplant recipient; Patient Specialist, University Transplant Center San Antonio; AAKP National Board of Director and National Ambassador; member, AAKP Public Policy Committee; 2020 PVSA recipient " Dale Rogers (ID), former dialysis patient, current transplant recipient; AAKP National Board of Director and National Ambassador; member of AAKP Programs/Development Committee; AAKP Peer Mentor; 2020 PVSA recipient " Dr. Barry Smith (NY),Founder,Dreyfus Health Policy and Research Center; former President/CEO, The Rogosin Institute; AAKP National Board of Director; 2020 PVSA recipient " Dr. Jonathan Himmelfarb (WA), Co-Director, the University of Washington Center for Dialysis Innovation; Director, the Kidney Research Institute; Professor of Medicine and Adjunct Professor of Bioengineering; expert presenter, AAKP Global Summit on Kidney Disease Innovation and AAKP National Patient Meeting " Dr. William Fissell (TN), Medical Director, The Kidney Project; Associate Professor of Clinical Medicine, Vanderbilt University Medical Center; AAKP Medal of Excellence Award recipient; expert presenter, AAKP Global Summit on Kidney Disease Innovation, AAKP National Patient Meeting, and AAKP Policy Summit; profile feature, AAKP Innovator series " Dr. Shuvo Roy (CA), Technical Director, The Kidney Project; Professor, Departments of Bioengineering and Therapeutics Sciences and Surgery; 2021 KidneyX Artificial Kidney Prize Winner; AAKP Medal of Excellence Award recipient; expert presenter, AAKP Global Summit on Kidney Disease Innovation, AAKP National Patient Meeting, and AAKP Policy Summit PVSA Silver Medal: " Melissa Bensouda (TX), former transplant recipient, current home hemodialysis patient; AAKP National Ambassador; 2020 PVSA recipient " Dr. Muralidharan Jagadeesan (DC), Associate Professor of Medicine, the Division of Renal Diseases and Hypertension and Chairman of Transplant Medicine; Medical Director, Kidney-Pancreas Transplant Program at the George Washington School of Medicine and Health Sciences; Faculty and Planning Committee Member, AAKP/GWU Global Summit on Kidney Innovations; 2020 PVSA recipient " Katina Lang-Lindsey, PhD, LMSW (AL), former dialysis patient, current transplant recipient; Assistant Professor, A&M University; AAKP National Ambassador; 2020 recipient, AAKP Patient Safety Award; 2020 PVSA recipient " Dammeon Marshall, MSW (GA), MSW; kidney disease patient; self-employed/entrepreneur; AAKP National Ambassador; 2020 PVSA recipient " James Myers (IN), former dialysis patient, current transplant recipient; AAKP National Board of Director and National Ambassador; Chair, AAKP Strategic Communications Committee; Chair, AAKP Pediatric Kidney Pals Initiative; 2015 recipient, Inaugural AAKP National Social Media Education and Advocacy Award; 2020 PVSA recipient " Sharron Rouse (MD), former dialysis patient, current transplant recipient; AAKP National Ambassador; Founder, Kindness for Kidneys International; 2020 recipient, AAKP Support Group of the Year Award; Co-Chair, 2020 AAKP National Patient Meeting; AAKP Peer Mentor; 2020 PVSA recipient " Lana Schmidt, MBA (IL), former home hemodialysis patient, current transplant recipient; AAKP National Board of Director and National Ambassador; Member, AAKP Strategic Communications Committee; 2020 PVSA recipient PVSA Bronze Medal: " Catherine Campbell, DNP, RN, MBA, CHC, CCM, FACHE (TX), pre-emptive transplant recipient; AAKP National Board of Director and National Ambassador; Member, the Patient Engagement and Return of Results Committee and Community Advisory Board Committee for the National Institutes of Health Kidney Precision Medicine Project; Working Group Member, International T Cell-Mediated Rejection Project " Sara Eve Schaeffer, MBA, MA, RD (FL), AAKP National Board of Director; VP, Strategic Operations, Healthmap Solutions; former Executive Director, the Centers for Medicare and Medicaid Services' kidney contracts for Health Services Advisory Group " Shameka Ausborn (FL), former transplant recipient, current home hemodialysis patient; AAKP National Ambassador; AAKP Peer Mentor " Gitthaline "Candie" Gagne (PA), former dialysis patient, current transplant recipient; AAKP National Ambassador; Retired Navy Hospital Corpsman; Certified Surgical Technologist " Christine Hernandez, RN, BSN (IL), registered nurse, current in-center hemodialysis patient; AAKP National Ambassador " Terry Litchfield (WI), former caregiver to husband who was a long-term dialysis patient; AAKP National Ambassador " Roberta "Bobbie" Reed (PA), caregiver to son who is a transplant recipient; AAKP National Ambassador " Cecilia Santana (NY), former dialysis patient, current transplant recipient; AAKP National Ambassador; AAKP Peer Mentor; Wellness Ambassador, The Rogosin Institute " Mihi Wickramasinghe (CA), former transplant recipient, current peritoneal dialysis patient; AAKP National Ambassador " Leigh-Ann Williams (LA), current home hemodialysis patient; AAKP National Ambassador
Program Service Accomplishments Line 4d: National Awards Program	Additional information for Part III line 4d AAKP Center for Patient Education and Research AAKP firmly believes, as research has also shown, that patient and family member/caregiver education is an integral part of treatment and enhancing quality of life. Not educating a patient and their care partner about their condition and treatment options leaves the patient at risk for complications as well as the possibility of not selecting a course of treatment best suited for them. Education is a simple and effective way to improve overall health and achieve better outcomes. In the same vein, AAKP is uniquely positioned to ensure the patient has a central role in research and other activities that are designed to determine optimal approaches and strategies for providing healthcare services, assistance programs, access to new products and services, etc. AAKP constituents represent all ages, modalities, ethnicities, disease states, and a variety of demographic indicators. AAKP's research capabilities have grown rapidly, and the Association has created a sophisticated database and expansive social media channels which allow AAKP to better connect and learn from its constituents. In turn, AAKP provides education to patients and caregivers on what it means to be involved in research initiatives as well as opportunities to get involved. From online surveys, interviews, focus groups, and clinical trial awareness campaigns - AAKP is focused on inserting important patient insight and preferences into research to help inform innovation, advance care and make a meaningful impact to improve lives - this means AAKP members are helping shape the future policies and discoveries that characterize kidney care! AAKP is known within the renal community as a leader in quality education; taking time to produce programs and materials that are current, relevant and address the most pressing issues patients and their families face. AAKP is deliberate in its development of educational programs, working closely with its Medical Advisory Board, health educators and fellow patients to create unbiased, reliable resources that are easily understood and beneficial to patients. AAKP routinely uses matrices to measure program outcomes to assess effectiveness and success as well as opportunities for enhancement. AAKP offers its programs in a variety of mediums to ensure we reach as many patients as possible (print, online/web-based, smart devices, live/in-person). Patient Pocket Guides: This brochure series offers a template for AAKP to develop a number of convenient, pocket sized guides that focus on a variety of important healthcare topics that patients can keep with that list top questions to ask their healthcare team to better understand/manage conditions. " AAKP Pocket Guide to Managing Kidney Disease: This Pocket Guide is a tool to help patients and caregivers have more effective dialogue with their healthcare teams. It includes 5 Key Questions to Ask your Doctor/Medical Specialist, as well as additional questions for each stage of Chronic Kidney Disease. " AAKP Pocket Guide to Managing High Potassium: The Pocket Guide is a tool to help kidney patients and caregivers have more effective dialogue with their healthcare teams about the risks associated with high potassium levels and the best way to manage it. " AAKP Pocket Guide to Managing Chronic Kidney Disease Associated Pruritus: The Pocket Guide is a tool to help kidney patients and caregivers have more effective dialogue with their healthcare teams about Chronic Kidney Disease Associated Pruritus (CKD-aP), moderate to severe itching associated with dialysis, and the best way to manage it. Cystinosis Patient Education and Activity Scholarship Program: While a variety of factors may cause an individual to be diagnosed with kidney disease, genetic and rare causes can be especially difficult for patients and family members to manage. Understanding the need to support individuals who have kidney diseases caused by a genetic or rare condition, AAKP has expanded its education, advocacy efforts and services to those affected. In support of AAKP's Pediatric and Rare Disease Initiatives, AAKP launched its Cystinosis Patient Education and Activity Scholarship Program for those affected with cystinosis in 2019. The objective of the scholarship program is to provide an exclusive opportunity for people living with cystinosis to provide inspiration, further their education and purse opportunities toward long-term career goals and life aspirations. This scholarship program is open to individuals diagnosed with cystinosis. Scholarship funds are available to age groups 5-17 years of age and 18+. To date, this program has funded 20 scholarships, totally over $50,000. KidneyWorks: The KidneyWorks Initiative research and policy collaboration aims to help Americans with chronic kidney disease who are not on dialysis maintain their jobs and slow their disease. KidneyWorks seeks to reduce disability and dependency and help people with ND-CKD remain active, productive, taxpaying citizens by taking proactive steps to educate patients, families, clinicians, and lawmakers and enact work-friendly practices and policies. " Phase One (Completed) Phase One included a national stakeholder meeting, preparing, and releasing a policy White Paper and Executive Summary, conducting national media rollout, and developing www.kidneyworks.org. The National Roundtable held in Washington, D.C. in June 2016 include sectors of the kidney community - patients, non-profits, professionals, members of industry and representatives from Federal government. The comprehensive KidneyWorks White Paper and Executive Summary was formally and publicly released in July 2017. The report identified barriers to patients' desire and ability to keep working and outlined a comprehensive strategy to remove them. The National Media rollout included more than 800 media websites and channels featuring KidneyWorks and the White Paper, including Fox Business News and Nephrology News & Issues. " Phase Two (Underway) Phase Two will use strategies identified in Phase One to develop interventions to help people with ND-CKD slow their disease progression and keep their jobs, including targeted messaging, tools and resources, telephone helpline support, and a robust database to track contacts and outcomes. " Phase Three (2022+) Phase Three will include evaluation of the impact of KidneyWorks by using the database and conducting outcomes research. Fabry Disease Diagnostic and Education Project: AAKP and Emory University have partnered to conduct an educational research project aimed at providing free genetic testing to individuals affected and at-risk for Fabry Disease. The research findings will help identify markers to Fabry that in turn will allow patients affected be diagnosed earlier in the disease state and begin intervention and treatment immediately. AAKP continues to develop many educational resources such as medical articles, brochures and webinars highlighting the advancements in Fabry Disease, best practices and the project's research findings. AAKP National Patient Meeting: The AAKP National Patient Meeting is the largest gathering of kidney patients and their care-partners in the U.S. Due to the Coronavirus pandemic, and for the safety of the AAKP professional team, speakers and audience (comprised of fellow kidney patients, healthcare professionals and industry/Federal agency partners), the 2021 National Patient Meeting was held online. The 2021 virtual patient meeting enabled AAKP to engage its national members and furthermore a global audience. The sophisticated platform AAKP used for the meeting allowed registrants to view general and breakout sessions; engage with speakers and fellow attendees; participate in a virtual exhibit hall and engage with vendor representatives in real-time; join virtual focus groups; and much more. AAKP featured several distinguished panelists and speakers, including but not limited to renowned healthcare professionals, researchers, patient experts, industry partners, and government agency representatives. All sessions are available post-event, OnDemand, for enduring education. AAKP is committed to making certain our events, like the Annual Patient Meeting, are disseminated to the widest audience of kidney consumers and decision-makers possible. Patient Engagement & Awareness Program: As a leading voice in the patient community, AAKP is uniquely positioned to assist companies interested in understanding the patient experience by connecting them directly to the thousands of patients, family members and caregivers in our database. AAKP's propriety database and engaged community of patients, creates a valuable resource to companies targeting the kidney patient population for market research and/or raising awareness on clinical trial opportunities.
Program Service Accomplishments Line 4d: National Awards Program	Medal of Excellence Award: The Medal of Excellence Award is the Association's highest honor for kidney healthcare professionals and is designed to elevate national and international figures who have been at the forefront of advancements in kidney care and patient empowerment. The award recognizes professionals who are committed to improving and extending the lives of all kidney patients through advocacy, research, technology and quality-driven treatments that protect patient dignity and fully align with patient aspirations. This prestigious award program recognizes a variety of professionals within the health care team including: nephrologists, transplant surgeons, transplant professionals, nurses, social workers, dietitians and dialysis technicians. Jenny Kitsen Patient Safety Award: Established in 2013 by the Network of New England Board of Directors to continue the patient safety work of the nonprofit organization led by Jenny Kitsen, former AAKP Board of Director. That organization held the CMS contract for ESRD Network 1 for 35 years, from 1977-2012. The Network staff, patients and professional volunteers who supported Network activities made a number of innovative contributions to the ESRD Network Program. Under Ms. Kitsen's direction, with the Board guidance, the New England Network organization became known for its leadership in patient safety. The AAKP has accepted an endowment from the Network of New England Board of Directors to honor Ms. Kitsen. The award funds a lecture or program that advances new approaches for increasing kidney patient safety knowledge and/or the dissemination of new research pertaining to effective safety procedures among medical professionals responsible for patient safety. In 2022, AAKP granted its first international safety recognition, honoring The Renal Patients Support Group (RPSG) of the United Kingdom. The RPSG participates in the AAKP Global initiative and is part of AAKP's expanding international collaborative of patient organizations focused on patient consumer-centered policies and innovations. Additional award recipients have included: Alan Kliger, MD, Chair, Nephrologists Transforming Dialysis Safety (NTDS), American Society of Nephrology (ASN); The Centers for Disease Control and Prevention; Satellite Healthcare; National Kidney Foundation; National Renal Administrators Association; A.T. Still University of Oral Health; All Kidney Patients Support Group; Renal Physicians Association; American Nephrology Nurses Association; and the Forum of ESRD Networks. AAKP Healthline Online Webinars: AAKP HealthLine is a one-hour FREE webinar program educating patients and caregivers on a variety of important topics all from the comfort of their home or office. A teleconference option is available for each program should the registrant not have computer access. All HealthLine programs are recorded and archived at www.aakp.org/aakp-healthline. Webinars are hosted monthly, recorded and archived on the AAKP website for enduring education. The archived webinars continue to be in the top five visited pages of the website. Throughout 2021, AAKP hosted a number of COVID-19 focused webinars with allied partners including the Centers for Disease Control and Prevention; the Veterans Affairs Administration; the American Society of Transplantation; and the American Society of Transplant Surgeons. In 2020, AAKP expanded this webinar program to include an Innovator series, which highlights the latest in research and innovation in the kidney space. AAKP Nutrition Program: " The AAKP Delicious! Series features a variety of kidney-friendly recipes for patients at all stages of kidney disease. All recipes have been carefully reviewed by renal dietitians and provide indications on what type of patient these recipes are most suited for. This recipe program has been favorably reviewed by the renal practice group of the Academy of Nutrition and Dietetics. Six editions of AAKP Delicious! are available, featuring more than 100 kidney-friendly recipes. " AAKP Nutrition Counter is a pocket-sized guide that lists the nutrient values for standard portions of more than 300 commonly used foods. Nutrient values listed include carbohydrates, fat, saturated fat, protein, calorie, sodium, potassium, and phosphorus levels - dietary values that must be closely monitored in kidney patients. Pocket Guides: This new brochure series offers a template for AAKP to develop several convenient, pocket-sized guides that focus on a variety of important healthcare topics that patients can keep with that list top questions to ask their healthcare team to better understand/manage conditions. "Understanding" Series: This workbook series covers a variety of important topics such as: Hemodialysis Options, Access Options, PD Options, Home Hemodialysis, Anemia, Iron, Depression, Fabry Disease, Hepatitis C, Kidney Transplantation, Gout, Kidney Stones, and Proteinuria. All brochures are available in print and online pdf. Kidney Beginnings: This workbook introduces chronic kidney disease and is designed for individuals recently diagnosed or with risk factors such as diabetes and hypertension. The various chapters address common topics for individuals with or at-risk for kidney disease such as: diabetes, hypertension, common medical test, common medications, emotional issues, diet/nutrition, exercise, employment and much more. Patient Plan Series: These four phased workbook series are designed to provide individuals with the information they need as they progress through kidney disease. The information is divided among the four books to allow a patient to advance when they are ready and learn information in a manageable way that allows for the greatest impact on behavioral changes. aakpRENALIFE: aakpRENALIFE is the official flagship magazine of the Association. Produced bi-monthly, the articles and information are educational in nature and designed to be relevant for patients regardless of stage of kidney disease or modality option. Content is made available online as well so that patients and caregivers have access to specialty articles at any time post-production. E-newsletters: are distributed monthly and cover current news and issues for individuals with chronic kidney disease, regardless of stage or modality.
Program Service Accomplishments Line 4d: National Awards Program	AAKP Center for Patient Engagement and Advocacy: The AAKP has been a national leader in patient advocacy and education for over 50 years - and is the largest fully independent and patient-governed organization in the kidney ecosystem. AAKP is highly regarded across the Federal government among both career and appointed policy-makers and our influence in the Executive Branch and the U.S. Congress transfers across transitions and elections cycles due to our massive network of relationships and long-held reputation as an independent voice for patients. AAKP believes that patients and industry must be at the table together and engaged at all levels of decision-making whenever the Federal government seeks to implement wide-ranging initiatives that impact innovation and shape future access to care options for individuals affected by kidney diseases. AAKP fundamentally understands that kidney disease and the health and treatment of kidney patients pose a significant impact on the American taxpayer and the national economy. The cost of kidney disease alone invites constant and intense interest and concern within the Federal government and the U.S. Congress. The costs associated with the disease have spurred multiple Federal initiatives in the past several years designed to increase positive patient outcomes, reduce spending and increase efficiencies. The move by the Federal government to examine and re-examine many of the cost-drivers within healthcare spending, and specifically within the ESRD program, represents a key reason why AAKP is working aggressively to build our capacities to raise the independent patient voice throughout the Federal policy-making process. In order for AAKP to maintain our leadership in protecting patient interests, and the overlapping interests among allies throughout the broader kidney community including the pharmaceutical industry and providers, we intend to grow our membership numbers, advance our National AAKP Ambassador Initiative, expand our reach internationally and equip kidney patients across the globe with proven and cost-effective training and technologies that make an impact on the policy process. The Center for Patient Engagement and Advocacy was created to leverage AAKP's increased profile and influence in the national public policy process and to expedite implementation of our national strategy to vastly expand patient involvement in the decisions impacting their health outcomes. The AAKP Center for Patient Engagement and Advocacy was created in 2014 to leverage AAKP's increased profile and influence in the national public policy process and to expedite implementation of our National Strategy to vastly expand patient involvement in the decisions that impact their health outcomes. The Center for Patient Engagement and Advocacy brings, under one focused area, all AAKP efforts to build patient and family/caregiver membership in AAKP as well as their participation in existing and emerging AAKP patient health engagement and advocacy programs. At the heart of this Center is the AAKP Ambassador Initiative, launched in 2017, the program has grown to more than 160 + Ambassadors in nearly all 50 states plus D.C. In 2019, AAKP launched the Global arm of this initiative and now has Global Ambassadors in countries such as Ireland, Canada, Argentina, United Arab Emirates and Puerto Rico. Ambassadors are AAKP's most engaged volunteers who utilize their personal experiences and professional skills to contribute to both the AAKP mission and the larger kidney community based on their desire to serve a cause larger than themselves. These individuals also allow AAKP to expand our reach and resources to make a positive impact at the state and local level and globally. Since 2018, AAKP has conducted the largest virtual kidney voter registration drive in America, the "I am a Kidney Voter" campaign, which has registered patients in every state. #IAmAKidneyVoter, #KidneyVoter. Major programs within this Center include the Decade of the Kidney, the Global Summit on Kidney Innovation, the Public Policy Summit, and the Ambassador Initiative. Additionally, as part of the AAKP National Strategy, the Center for Patient Engagement and Advocacy works to engage, train, certify and deploy kidney patients in ways that are the most effective at elevating the patient voice within Federal policy-making circles. This includes critical times when national legislation, health program implementation, regulations or potential delays in the pharmaceutical approval process pose a concern to patient access to quality care or their future healthcare outcomes. AAKP is engaging and encouraging kidney patients and caregivers to participate in substantive opportunities for effective patient engagement and advocacy. AAKP operates via key distinctives and principles: 1. Elevate patient voice in national issues and across drug, diagnostic and device development 2. Protect the unique relationship between patients and their doctors 3. Educate patients and preserve their access to choices as informed consumers of healthcare 4. Maintain full independence in all national policy and decisions - never surrender your letterhead 5. Honor the principle of "no surprises" among trusted allies and Federal government officials AAKP has a history of advocating on important issues affecting patients' care, treatment, options, medications and such. The Advocacy Program helps support initiatives such as: Capitol Hill Day visits, participation in meetings/seminars/conventions, public policy, Communication, research issues affecting patients and practical tools that explain how to be more effective advocates.
Program Service Accomplishments Line 4d: National Awards Program	The Decade of the Kidney The Decade of the Kidney is a transformative announcement AAKP made in June of 2019 at its 2nd Annual National Policy Summit in Washington, D.C. designed to unite the community around a central thought - or a "big idea." From 2020-2030, during the Decade of the Kidney, we will see even greater contributions from every sector of our society and every discipline. These include medicine, science, academia, electedofficials, industry, media, entertainment, government, the military and insights from our veteran populations. These sweeping changes will not be limited to our shores as Americans - they will incorporate the vibrant contributions of scientists, researchers and clinicians around the world whose achievements are moving us closer to addressing the toughest kidney diseases. As patients we know that kidney disease affects people everywhere - it does not discriminate, it knows no political affiliation and it recognizes no border. To accelerate change, AAKP believes that a far larger strategic context and message is needed to unite a broader base of Americans and far more communities behind ongoing efforts to fight kidney disease and give hope to the 40 million Americans who suffer from kidney diseases. We believe that the Decade of the Kidney will do precisely that - help explain to the general public and national policy leaders that each of our singular efforts and innovations underway in kidney disease are in fact part of a far larger national effort to save and improve lives for those who suffer from kidney disease - and those yet to be diagnosed. AAKP recommitted itself to this original formula and strategy to gain new national relevance; exponentially greater engagement and growth among kidney patients and their families; and far greater influence to push for greater patient choice and more innovative care options for patients. Working together, AAKP and its members and allies have achieved profound impacts in the past several years - including legislation that allows HIV to HIV organ transplants, lower prescription drug costs and, most recently, AAKP contributed to the White House Executive Order on Advancing American Kidney Health and the Department of Health and Human Services (HHS) initiatives to fight kidney disease. AAKP also believes that by uniting all sectors of the kidney community under one strategic theme - it will be far easier to secure additional media and grassroots support, national research funding and public understanding for kidney disease. Global Summit on Kidney Innovation The Global Summit is a two-day event in Washington, D.C. designed to engage the top international experts in the field of kidney care including healthcare professionals, academics, government leaders and regulators, industry experts, entrepreneurs, and patient advocates. This event is a partnership of the George Washington University School of Medicine, one of the top medical schools in the nation with an internationally recognized kidney care program, and the American Association of Kidney Patients (AAKP), the oldest and largest fully independent kidney patient organization in the United States. The 2020 Global Summit hosted virtually in response to the Coronavirus pandemic, highlights include: Over thousands of registrants, 20 special medical and patient expert sessions, 5 countries represented by speakers, and 70 countries reached via the live stream. Panel presentations and discussions were recorded and made available OnDemand on the AAKP website for enduring education. Speakers Bureau The AAKP Speakers Bureau, under the AAKP Center for Patient Engagement and Advocacy, provides the public, private sector companies and non-profit organizations with highly knowledgeable experts committed to advancing the AAKP mission through personal experiences and expertise. Speakers include AAKP National Board Members and National Ambassadors. Each speaker is well-prepared to talk before large and small audiences. Together, our speakers share a wide range of disease and treatment experiences, and their combined professional portfolios include published articles and books, participation in key government initiatives, industry focus groups and clinical trials, and testimony before Federal agencies. The AAKP Speakers Bureau is AAKP's contribution to the growing movement to generate greater public understanding of kidney disease nationwide, from local towns to the corridors of government in our nation's capital. AAKP Veterans Health Initiative The AAKP Veterans Health Initiative (VHI), based within the AAKP Center for Patient Engagement and Advocacy, is designed to advance research, innovation and policies aimed at safeguarding the highest standards in kidney care and treatment for veterans managing kidney disease both inside and outside the VA medical system. AAKP utilizes sophisticated social media and grassroots technologies to engage patients, medical professionals, and the public and to voice their concerns among policymakers. Veterans and their families face many unique challenges related to managing their healthcare and this is especially true for veterans who suffer from kidney and other complex, chronic diseases. AAKP is committed to making its fellow veterans have their voice heard, retain access to the care they have earned and are legally entitled to at the VA and elsewhere and gain the benefit of new research and innovations in the realms of biologics, diagnostics, and devices. Capitol Hill Day Visits: These educational visits, hosted virtually in 2021-22, engage patients, care partners and healthcare professionals with their legislative representatives and staff to discuss current policy issues that affect patient care and quality of life. Participants are provided training on how to conduct respectful and substantive meetings before ever visiting Capitol Hill. AAKP also partners with medical professional organizations when policy issues related to patient services overlap with our strategic issue agenda. These organizations include, but are not limited to the following: " Alliance for Home Dialysis " Alport Syndrome Foundation " American Kidney Fund " American Society of Nephrology " American Society of Pediatric Nephrology " American Society of Transplantation " American Society of Transplant Surgeons " Kidney Community Hill Day (a collaborative effort of over twelve national organizations) " Kidney Health Initiative " Medical Education Institute " National Kidney Foundation " National Renal Administrators Association " PKD Foundation " Renal Physicians Association " TransplantFirst Academy, and more. Contact AAKP for a full list of partners. In 2021-2022, AAKP has conducted over 600 Hill visits, independently and jointly with key allied organizations. AAKP's Ambassador Initiative: The AAKP Ambassador Initiative is part of our Center for Patient Engagement and Advocacy. Ambassadors are our most engaged volunteers - seasoned experts on kidney disease, dialysis, transplant, and living kidney donation. Ambassadors utilize their personal experiences and professional skills to contribute to both the AAKP mission and the larger kidney community based on their desire to serve a cause larger than themselves. AAKP helps provide Federal officials with the patient input they seek, through our Ambassadors' engagement. Ambassadors maintain relationships and communications with their elected leaders to be sure kidney disease is on their radar. They participate in focus groups, roundtables, Technical Evaluation Panels (TEPs), surveys, clinical trials, public testimony before Federal agencies, and more. Throughout 2021-22, AAKP expanded this initiative to include International Ambassadors from countries including, but not limited to: Argentina, United Kingdom, Ireland, United Arab Emirates, Germay, and Canada. AAKP Policy Summit: AAKP is a nationally recognized leader in patient education and advocacy and our independent insights are highly regarded and relied upon by government agencies, elected and appointed national policymakers and policy influencers. With 50 years of effective patient engagement experience, AAKP knows that patients, government, researchers, professionals and industry working collaboratively together is the fastest way to transplant new innovations in kidney care into care solutions that impact patient health outcomes. The Policy Summit brings together key influencers from across all sectors of the policy spectrum for a two-day Summit that addresses the current state of kidney care at the crossroads of innovation, regulation and payment.
Program Service Accomplishments Line 4d: National Awards Program	Strategic Partnerships and Alliances: AAKP has maintained our national reputation as a trusted and independent voice for patients by both maintain our independence and through a select and targeted series of collaborative relationships with other non-profit professional and patient organizations. Before AAKP collaborates with any organization, we pose several questions to assess their credibility in our order to protect our organization and the patient interests we represent. These questions include: 1. Will our association with this organization discredit the AAKP mission and legacy? 2. Will our association with this organization confuse or contradict the AAKP message? 3. Will our association with this organization turn away potential long-term allies? 4. Will our association with this organization discourage elected/career policy-maker interest or support of policy goal? 5. Will our association with this organization fulfill a negative narrative already underway about your issue/community? Our current strategic partnerships and alliances include but are not limited to: " Academy of Nutrition and Dietetics " Alliance for Home Dialysis " Alport Syndrome Foundation " Alliance for Gout Awareness " Alliance for a Stronger FDA " American Kidney Fund " American Nephrology Nurses Association " American Society of Nephrology " American Society of Pediatric Nephrology " American Society of Transplant Surgeons " American Society of Transplantation " Dialysis Clinic, In. " Emory University " ESRD Rockstars " For Kidney's Sake, Inc. " Forum of ESRD Networks " Friends of NIDDK " Friends of HRSA " Home Dialyzers United " IGA Nephropathy Foundation of America " International Home Dialysis Roundtable " Kaiser Permanente GA " Kidney Health Initiative " Making Dialysis Safer Coalition " Medical Education Institute " National Association of Nephrology Technicians " National Kidney Foundation " National Renal Administrators Association " National Psoriasis Society " NephCure Kidney International " Oxalosis and Hyperoxaluria Foundation " Patient Access to Pain Relief (PAPR) " Patient Alliance for Drug Safety Protections " Polycystic Kidney Disease Foundation " Precision Medicine Coalition " ReMend " Renal Pathology Society " Renal Physicians Association " Renal Support Network " Rogosin Institute " Scientific Registry of Transplant Recipients " Society of Transplant Social Workers " Southeastern Kidney Transplant Coalition " TRIO - Transplant Recipients International Organization " Veterans Transplant Association, and more. Contact AAKP for a full list of partners. Federal Agency Engagement: Over the course of the past year, and again as a result of our national engagement strategy, AAKP has been heavily involved with multiple Federal agencies. AAKP has traditionally worked very closely with Federal agencies since our organization leads national efforts to establish the End Stage Renal Disease Program (ESRD), administered since 1973 by Department of Health and Human Services under the Centers for Medicare and Medicaid Services (CMS). AAKP values the civil service of the United States and has maintained strong relationships with programs, agencies and personnel under every Presidential Administration since 1973 and is non-partisan in our engagements with the U.S. civil service. Below are just a few of the agencies AAKP engaged with: " Center for Disease Control and Prevention (CDC) " White House Office of Science and Technology Policy (OSTP) " White House, National Economic Council (NEC) " U.S. Department of Health and Human Services (HHS) " U.S. Department of Labor (DOL) " U.S. Department of Defense (DoD) " DOL/Office of Disability Employment Programs (ODEP) " HHS/Centers for Medicare and Medicaid Assistance (CMS) " HHS/Center for Medicare and Medicaid Innovation (CMMI) " HHS/Food and Drug Administration (FDA) " HHS/National Institutes of Health (NIH) " HHS/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) " HHS/Health Resources and Services Administration (HRSA) " Veteran's Administration (VA) In addition to these agency engagements, AAKP has served as the Chair of the CMS Technical Evaluation Panel (TEP) for the CMS Dialysis Facility Compare 5 Star Rating Program as well as multiple other TEP's. AAKP also holds multiple seats on the Board and subcommittees of the Kidney Health Initiative - an FDA/ASN breakthrough collaborative and is actively involved as well in the Clinical Trials Transformation Initiative, another breakthrough collaborative between the FDA and Duke University. AAKP leadership holds positions within the NIH Kidney Precision Medicine Project, the FDA Patient Engagement Advisory Panel, and the CDC Healthcare Infection Control and Advisory Council. Part VI llb: The Form 990 is reviewed in detail by the Finance Committee. The Finance Committee approves the return. Copies of the Form 990 are provided to all Board members prior to the return being filed. Part VI 12c: All members of the Board of Directors and employees of the organization receive a copy of the conflict of interest policy. The Executive Director and all Board members are required to complete and sign a written statement that they have been and are in compliance with this policy. 15a: The Executive Committee conducts an annual review of the Executive Director's performance and recommends any adjustment to salary to the Board of Directors. The Board of Directors approves raises for the Executive Director and approves the overall salary levels for all employees.

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 51056K

Schedule O (Form 990) 2021

Additional Data

Software ID:
Software Version:

1	Briefly describe the organization’s mission or most significant activities: AAKP is dedicated to improving the lives and long-term outcome of kidney patients. Cont on Sch O.
2	Check this box
3	Number of voting members of the governing body (Part VI, line 1a) ........	3	14
4	Number of independent voting members of the governing body (Part VI, line 1b) .....	4	14
5	Total number of individuals employed in calendar year 2021 (Part V, line 2a) ......	5	6
6	Total number of volunteers (estimate if necessary) .............	6	200
7a	Total unrelated business revenue from Part VIII, column (C), line 12 ........	7a	56,910
b	Net unrelated business taxable income from Form 990-T, Part I, line 11 .........	7b	0

		Prior Year	Current Year
8	Contributions and grants (Part VIII, line 1h) .........	1,196,542	1,944,903
9	Program service revenue (Part VIII, line 2g) .........	858,386	531,891
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d ) ....	0	0
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	-335	-3,856
12	Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)	2,054,593	2,472,938
13	Grants and similar amounts paid (Part IX, column (A), lines 1–3 )...	21,040	8,754
14	Benefits paid to or for members (Part IX, column (A), line 4).....	0	0
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10)	508,743	623,647
16a	Professional fundraising fees (Part IX, column (A), line 11e) .....	0	0
b	Total fundraising expenses (Part IX, column (D), line 25) 34,437
17	Other expenses (Part IX, column (A), lines 11a–11d, 11f–24e)....	744,028	944,844
18	Total expenses. Add lines 13–17 (must equal Part IX, column (A), line 25)	1,273,811	1,577,245
19	Revenue less expenses. Subtract line 18 from line 12.......	780,782	895,693
		Beginning of Current Year	End of Year
20	Total assets (Part X, line 16).............	1,743,144	2,636,113
21	Total liabilities (Part X, line 26).............	715,511	712,787
22	Net assets or fund balances. Subtract line 21 from line 20.....	1,027,633	1,923,326

Sign Here

	Signature of officer	Date

	Type or print name and title


4a	(Code: ) (Expenses $ 358,480 including grants of $ ) (Revenue $ )
	Center for Patient Engagement and Advocacy: The AAKP has been a national leader in patient advocacy and education for over 50 years - and is the largest fully independent and patient-governed organization in the kidney ecosystem. AAKP is highly regarded across the Federal government among both career and appointed policymakers and our influence in the Executive Branch and the U.S. Congress transfers across transitions and elections cycles due to our massive network of relationships and long-held reputation as an independent voice for patients. AAKP believes that patients and industry must be at the table together and engaged at all levels of decision-making whenever the Federal government seeks to implement wide-ranging initiatives that impact innovation and shape future access to care options for individuals affected by kidney diseases. AAKP fundamentally understands that kidney disease and the health and treatment of kidney patients pose a significant impact on the American taxpayer and the national economy. The cost of kidney disease alone invites constant and intense interest and concern within the Federal government and the U.S. Congress. The costs associated with the disease have spurred multiple Federal initiatives in the past several years designed to increase positive patient outcomes, reduce spending, and increase efficiencies. The move by the Federal government to examine and re-examine many of the cost-drivers within healthcare spending, and specifically within the ESRD program, represents a key reason why AAKP is working aggressively to build our capacities to raise the independent patient voice throughout the Federal policy-making process. In order for AAKP to maintain our leadership in protecting patient interests, and the overlapping interests among allies throughout the broader kidney community including the pharmaceutical industry and providers, we intend to grow our membership numbers, advance our National AAKP Ambassador Initiative, expand our reach internationally and equip kidney patients across the globe with proven and cost-effective training and technologies that make an impact on the policy process. The Center for Patient Engagement and Advocacy was created to leverage AAKP's increased profile and influence in the national public policy process and to expedite implementation of our national strategy to vastly expand patient involvement in the decisions impacting their health outcomes. The AAKP Center for Patient Engagement and Advocacy was created in 2014 to leverage AAKP's increased profile and influence in the national public policy process and to expedite implementation of our National Strategy to vastly expand patient involvement in the decisions that impact their health outcomes. The Center for Patient Engagement and Advocacy brings, under one focused area, all AAKP efforts to build patient and family/caregiver membership in AAKP as well as their participation in existing and emerging AAKP patient health engagement and advocacy programs. At the heart of this Center is the AAKP Ambassador Initiative, launched in 2017, the program has grown to more than 170 + Ambassadors across the U.S. In 2019, AAKP launched the AAKP Global, the global arm of this initiative, and now has Global Ambassadors in countries such as Ireland, Canada, Argentina, United Arab Emirates, Puerto Rico, and many more. Ambassadors are AAKP's most engaged volunteers who utilize their personal experiences and professional skills to contribute to both the AAKP mission and the larger kidney community based on their desire to serve a cause larger than themselves. These individuals also allow AAKP to expand our reach and resources to make a positive impact at the state and local level and globally. Major programs, initiatives, and campaigns within this Center also include The Decade of the Kidney, the Annual Global Summit on Kidney Innovation, the Annual Public Policy Summit, and the AAKP Action Center - which includes the AAKP KidneyVotervoter registration campaign and the AAKP Patient Voice Patient Choice initiative. Additionally, as part of the AAKP National Strategy, the Center for Patient Engagement and Advocacy works to engage, train, certify and deploy kidney patients in ways that are the most effective at elevating the patient voice within Federal policy-making circles. This includes critical times when national legislation, health program implementation, regulations or potential delays in the pharmaceutical approval process pose a concern to patient access to quality care or their future healthcare outcomes. AAKP is engaging and encouraging kidney patients and caregivers to participate in substantive opportunities for effective patient engagement and advocacy. To date, AAKP has developed and makes available OnDemand over a dozen Advocacy and Engagement Skills Training sessions. AAKP operates via key distinctives and principles: 1. Elevate patient voice in national issues and across drug, diagnostic and device development2. Protect the unique relationship between patients and their doctors3. Educate patients and preserve their access to choices as informed consumers of healthcare4. Maintain full independence in all national policy and decisions - never surrender your letterhead5. Honor the principle of "no surprises" among trusted allies and Federal government officials AAKP has a history of advocating on important issues affecting patients' care, choice and access to approved treatments, increased research and innovation, and much more. The Advocacy Program helps support initiatives such as: Capitol Hill Day visits, participation in meetings/seminars/conventions, public policy, Communication, research issues affecting patients and practical tools that explain how to be more effective advocates.

4b	(Code: ) (Expenses $ 241,777 including grants of $ ) (Revenue $ )
	Annual National Patient Meeting: Each year, AAKP hosts a timely and interactive patient meeting featuring a diverse line-up of speakers crossing all sectors of the kidney community including the top influencers in kidney care from Federal government, medical professionals, academia, private industry, and non-profit professional organizations; along with an interactive exhibit hall allowing participates to engage with various kidney-related companies/organizations. The 2022 National Patient Meeting was titled "Patient Consumers: Leaders for Research and Innovation." The 2022 meeting highlighted expanding kidney patient impacts on all aspects of innovations in kidney medicine, including research, clinical trials, product design, market delivery, and timely patient access to new drugs, devices, and diagnostics. The virtual meeting broke all previous engagement records and drew patients from 46 states and territories. The agenda featured 25 sessions and over 60 patient expert, government, medical, and industry speakers. All 2022 National Patient Meeting presentations will be available OnDemand through the AAKP website and AAKP YouTube Channel.

4c	(Code: ) (Expenses $ 547,385 including grants of $ ) (Revenue $ )
	Patient Information and Education:AAKP is dedicated to improving the lives and long-term outcome of kidney patients through education, advocacy, patient engagement and the fostering of patient communities. AAKP fights for early disease detection and appropriate diagnosis of rare/genetic conditions; increased kidney transplantation and pre-emptive transplantation; full patient choice of either in-center or home dialysis; protection of the patient/physician relationship; promotion of research and innovation including artificial wearable and implantable kidneys and xenotransplantation; and the elimination of barriers for patient access to available treatment options. At AAKP, we1. Educate: patients & caregivers on important issues so patients can better understand their condition and make informed decisions on their care options which align with their life's goals and aspirations. AAKP is a recognized leader for patient-centered education - continually developing high quality, professionally written, edited and reviewed material.2. Advocate: for policies that improve treatment and extend life for kidney disease patients - always defending patient choice. AAKP has been the independent patient voice - advocating for improved access to high-quality healthcare through regulatory and legislative reform at the Federal level. The Association's work has improved long-term outcomes in both quality of health and the ability for patients and family members affected by kidney diseases to lead a more productive and meaningful life.3. Define: "patient engagement" as a substantive tool to impact policy & health outcomes.4. Community: AAKP is leading the effort to bring kidney patients together to promote community, conversations and to seek out services that help maximize patients' everyday lives.The AAKP fulfills our educational mission through an extensive patient education program to inform and educate kidney patients, their families, and the general public on kidney diseases. To meet the needs of all individuals, AAKP offers its programs in a variety of mediums: print, web-based and live (in-person). AAKP services more than one million individuals annually via its various educational programs and communication platforms. AAKP's bimonthly magazine, aakpRENALIFE, averages more than 400,000 readers/views annually and includes information about the latest news, education, policy/legislative issues, innovations/research occurring in the kidney community and patient/caregiver/living donor profiles. The magazine is also distributed to over 7,000 dialysis centers nationwide and has a substantial afterlife as it remains in dialysis centers for quite some time after mailing. aakpRENALIFE is available via print/digital medium and is archived on www.aakp.org for a term of one year.AAKP's monthly e-newsletters, collectively, were delivered more than 250,000 times during this year - including aakpRENALFLASH (designed for individuals on dialysis); Kidney Transplant Today (designed for individuals with or interested in a kidney transplant); Kidney Beginnings (designed for and new patients learning more about their disease; At Home with AAKP (designed for individuals on or interested in home dialysis therapies) and AAKP Pediatric Kidney Patients (designed for peds, adolescents and their families). AAKP hosts its monthly HealthLine webinar series for patients and the public on timely and relevant topics such as managing risk factors for kidney disease (diabetes/hypertension); understanding dialysis options; kidney transplantation; how to choose/change treatment options; diet/nutrition; importance of exercise; coping with a chronic illness, advocacy and social media; and more. These webinars are recorded and made available OnDemand to accommodate all schedules and needs and reach thousands annually. AAKP has expanded this webinar program to include an Innovator series, which highlights the latest research and innovation occurring in the kidney space.AAKP utilizes a variety of communication platforms to reach approximately one million individuals annually. Included in that reach is AAKP's social medial platforms: Facebook, Twitter, LinkedIn, Instagram, Pinterest, and YouTube Channel. AAKP's website (www.aakp.org) has over 420,000-page views annually. The website features the AAKP Center for Patient Research and Education and Center for Patient Engagement and Advocacy - including:" education (CKD, dialysis, transplant, co-related health conditions; causes of kidney disease; rare disease; nutrition); clinical trials/market research opportunities; Action Center (advocacy initiatives; policy issues; voter registration); patient engagement (Ambassador Initiative; Speakers Bureau; Veterans Health initiative; KidneyWorks; Support Groups), programs/events (National Patient Meeting; Cystinosis Scholarship Program, Medal of Excellence; Policy Summit; Global Summit; Patient Safety Program), and online store to download/purchase materials.

	(Code: ) (Expenses $ 68,666 including grants of $ 8,754 ) (Revenue $ 476,014 )
	National Awards ProgramSee Schedule O

4d	Other program services (Describe in Schedule O.)
	(Expenses $ 68,666 including grants of $ 8,754 ) (Revenue $ 476,014 )
4e	Total program service expenses1,216,308

1b	Sub-Total................
c	Total from continuation sheets to Part VII, Section A....
d	Total (add lines 1b and 1c)...........	150,000	0	0

(A) Name and business address	(B) Description of services	(C) Compensation





2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization 0

1a	Federated campaigns..		1a
b	Membership dues..		1b	578,900
c	Fundraising events..		1c	34,500
d	Related organizations		1d
e	Government grants (contributions)		1e	79,116

f	All other contributions, gifts, grants, and similar amounts not included above		1f	1,252,387

g	Noncash contributions included in lines 1a - 1f:$		1g

h Total. Add lines 1a-1f.......		1,944,903

		Business Code
2a	Annual Meeting	900099	434,487	434,487
b	Advertising and Magazi	900099	56,910		56,910
c	Inventory Sale	900099	25,494	25,494
d	Policy Summit	900099	15,000	15,000
e
f	All other program service revenue.
g	Total. Add lines 2a–2f .....		531,891

3 Investment income (including dividends, interest, and othersimilar amounts) ......
4 Income from investment of tax-exempt bond proceeds
5 Royalties...........
		(ii) Personal	(i) Real
6a	Gross rents			6a
b	Less: rental expenses			6b
c	Rental income or (loss)			6c
d	Net rental income or (loss).......
		(ii) Other	(i) Securities
7a	Gross amount from sales of assets other than inventory			7a
b	Less: cost or other basis and sales expenses			7b
c	Gain or (loss)			7c
d	Net gain or (loss).........
8a	Gross income from fundraising events (not including $ 34,500of contributions reported on line 1c). See Part IV, line 18 ....
			8a	2,463
b	Less: direct expenses ...		8b	7,352
c	Net income or (loss) from fundraising events..			-4,889			-4,889
9a	Gross income from gaming activities. See Part IV, line 19 ...
			9a
b	Less: direct expenses ...		9b
c	Net income or (loss) from gaming activities..
10a	Gross sales of inventory, less returns and allowances ..
			10a
b	Less: cost of goods sold ..		10b
c	Net income or (loss) from sales of inventory..
Business Code			Miscellaneous Revenue
11a	Other		900099	1,033	1,033
b
c
d	All other revenue ....
e	Total. Add lines 11a–11d ......			1,033
12	Total revenue. See instructions.....			2,472,938	476,014	56,910	-4,889

1	Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21 ....
2	Grants and other assistance to domestic individuals. See Part IV, line 22 ...........	8,754	8,754
3	Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16. .............
4	Benefits paid to or for members .......
5	Compensation of current officers, directors, trustees, and key employees ...........	150,000	93,450	53,850	2,700
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) .........
7	Other salaries and wages........	384,534	239,592	137,922	7,020
8	Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions) ....
9	Other employee benefits .......	48,235	30,053	17,305	877
10	Payroll taxes ...........	40,878	24,477	15,671	730
11	Fees for services (non-employees):
a	Management ......
b	Legal .........
c	Accounting ...........	278,823	222,525	56,298
d	Lobbying ...........
e	Professional fundraising services. See Part IV, line 17
f	Investment management fees ......
g	Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O)
12	Advertising and promotion ....	104,677	104,186		491
13	Office expenses .......
14	Information technology ......
15	Royalties ..
16	Occupancy ...........	39,555	24,645	14,191	719
17	Travel ............	18,156	18,156
18	Payments of travel or entertainment expenses for any federal, state, or local public officials .
19	Conferences, conventions, and meetings ....
20	Interest ...........
21	Payments to affiliates .......
22	Depreciation, depletion, and amortization ..	6,934	4,320	2,488	126
23	Insurance ...	2,446		2,446
24	Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a	Annual meeting and prog	331,772	330,265		1,507
b	Printing and Publicatio	87,733	83,229	414	4,090
c	Postage and shipping	33,892	21,761	9,505	2,626
d	Fees, dues and subscrip	16,084	751	2,061	13,272
e	All other expenses	24,772	10,144	14,349	279
25	Total functional expenses. Add lines 1 through 24e	1,577,245	1,216,308	326,500	34,437
26	Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here if following SOP 98-2 (ASC 958-720).

1	Cash–non-interest-bearing ........			1,573,305	1	2,204,420
2	Savings and temporary cash investments .........				2
3	Pledges and grants receivable, net ......				3
4	Accounts receivable, net .............			116,516	4	354,066
5	Loans and other receivables from any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .......
					5
6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B) ...
					6
7	Notes and loans receivable, net ...........				7
8	Inventories for sale or use ............			30,715	8	43,589
9	Prepaid expenses and deferred charges ......			13,553	9	20,838
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	62,207
b	Less: accumulated depreciation	10b	52,132	5,930	10c	10,075
11	Investments—publicly traded securities .				11
12	Investments—other securities. See Part IV, line 11 .....				12
13	Investments—program-related. See Part IV, line 11 ..				13
14	Intangible assets ...............				14
15	Other assets. See Part IV, line 11 ...........			3,125	15	3,125
16	Total assets. Add lines 1 through 15 (must equal line 33)...			1,743,144	16	2,636,113

17	Accounts payable and accrued expenses .....	41,458	17	115,660
18	Grants payable ...		18
19	Deferred revenue .........	588,261	19	597,127
20	Tax-exempt bond liabilities .........		20
21	Escrow or custodial account liability. Complete Part IV of Schedule D		21
22	Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .........
			22
23	Secured mortgages and notes payable to unrelated third parties ..	79,116	23
24	Unsecured notes and loans payable to unrelated third parties ..		24
25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17 - 24). Complete Part X of Schedule D	6,676	25	0
26	Total liabilities. Add lines 17 through 25..	715,511	26	712,787

	Organizations that follow FASB ASC 958, check here and complete lines 27, 28, 32, and 33.
27	Net assets without donor restrictions ..........	872,031	27	1,745,924
28	Net assets with donor restrictions ...........	155,602	28	177,402
	Organizations that do not follow FASB ASC 958, check here and complete lines 29 through 33.
29	Capital stock or trust principal, or current funds .....		29
30	Paid-in or capital surplus, or land, building or equipment fund ...		30
31	Retained earnings, endowment, accumulated income, or other funds		31
32	Total net assets or fund balances ...........	1,027,633	32	1,923,326
33	Total liabilities and net assets/fund balances ........	1,743,144	33	2,636,113

Name of organization American Association of Kidney Patients Inc

Part I Contributors	Contributors (see instructions). Use duplicate copies of Part I if additional space is needed.
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
RESTRICTED	,	$ RESTRICTED	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
Schedule B (Form 990) (2021)

Name of organization American Association of Kidney Patients Inc		Employer identification number 11-2306416

Part II	Noncash Property (see instructions). Use duplicate copies of Part II if additional space is needed.
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
Schedule B (Form 990) (2021)


Name of organization American Association of Kidney Patients Inc			Employer identification number 11-2306416
Part III Exclusively religious, charitable, etc., contributions to organizations described in section 501(c)(7), (8), or (10) that total more than $1,000 for the year from any one contributor. Complete columns (a) through (e) and the following line entry. For organizations completing Part III, enter the total of exclusively religious, charitable, etc., contributions of $1,000 or less for the year. (Enter this information once. See instructions.) $ Use duplicate copies of Part III if additional space is needed.

1a	Beginning of year balance ....
b	Contributions ...
c	Net investment earnings, gains, and losses
d	Grants or scholarships ...
e	Other expenditures for facilities and programs ...
f	Administrative expenses ....
g	End of year balance ......

1a	Land .....
b	Buildings ....
c	Leasehold improvements
d	Equipment ....	62,207	52,132	10,075
e	Other .....
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10(c).)..				10,075

(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1) Financial derivatives.........
(2) Closely-held equity interests........
(3)Other
(A)
(B)
(C)
(D)
(E)
(F)
(G)
(H)
Total. (Column (b) must equal Form 990, Part X, col. (B) line 12.)

(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-of-year market value

(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 13.)

1.(a) Description of liability	(b) Book value
(1) Federal income taxes

(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 25.)
2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740). Check here if the text of the footnote has been provided in Part XIII

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1	Total revenue, gains, and other support per audited financial statements .......			1	2,477,870
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:
a	Net unrealized gains (losses) on investments ....	2a
b	Donated services and use of facilities .........	2b	4,932
c	Recoveries of prior year grants ...........	2c
d	Other (Describe in Part XIII.) ............	2d
e	Add lines 2a through 2d .....................			2e	4,932
3	Subtract line 2e from line 1..................			3	2,472,938
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b .	4a
b	Other (Describe in Part XIII.) ...........	4b
c	Add lines 4a and 4b....................			4c	0
5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) ......			5	2,472,938

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1	Total expenses and losses per audited financial statements ...........			1	1,582,177
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:
a	Donated services and use of facilities .........	2a	4,932
b	Prior year adjustments ............	2b
c	Other losses ................	2c
d	Other (Describe in Part XIII.) ............	2d
e	Add lines 2a through 2d....................			2e	4,932
3	Subtract line 2e from line 1...................			3	1,577,245
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b ..	4a
b	Other (Describe in Part XIII.) ............	4b
c	Add lines 4a and 4b.....................			4c	0
5	Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.) ......			5	1,577,245

a	Mail solicitations	e	Solicitation of non-government grants
b	Internet and email solicitations	f	Solicitation of government grants
c	Phone solicitations	g	Special fundraising events
d	In-person solicitations